NBRVF — Nabriva Therapeutics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Annual cashflow statement for Nabriva Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2018 December 31st	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-115	-82.8	-69.5	-49.5	-57.2
Depreciation
Deferred Taxes
Non-Cash Items	37.5	10.7	9.13	4.39	6.52
Unusual Items
Purchased R&D
Other Non-Cash Items
Changes in Working Capital	4.03	-0.195	-11.4	-14.9	13.7
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Cash from Operating Activities	-72.7	-71.9	-71.3	-59.6	-36.7
Capital Expenditures	-0.229	-0.061	-0.113	-0.025	-0.211
Purchase of Fixed Assets
Other Investing Cash Flow Items	-4.38	0.392	-0.161	-0.056	-0.052
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-4.6	0.331	-0.274	-0.081	-0.263
Financing Cash Flow Items	-6.83	-1.99	-4.72	-3.83	-0.405
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	92.9	56.1	26.9	66.4	1.85
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	15.2	-15.6	-44.8	6.24	-35.3